These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38597738)

  • 21. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study.
    Zhang Q; Xu F; Liu S; Zhu S; Zhang S; Wu J; Wu S
    Liver Int; 2024 Sep; 44(9):2315-2328. PubMed ID: 38819640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.
    Mori K; Tanaka M; Sato T; Akiyama Y; Endo K; Ogawa T; Suzuki T; Aida H; Kawaharata W; Nakata K; Hosaka I; Umetsu A; Hanawa N; Furuhashi M
    Hepatol Res; 2024 Aug; ():. PubMed ID: 39110552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MetALD: Does it require a different therapeutic option?
    Marek GW; Malhi H
    Hepatology; 2024 May; ():. PubMed ID: 38820071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Not Available].
    Hansen CD; Lindvig KP; Grønbæk H; Gluud LL; Thiele M; Krag A
    Ugeskr Laeger; 2024 May; 186(19):. PubMed ID: 38808766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting.
    Yang K; Chung BS; Ryu T
    Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Canivet CM; Boursier J; Loomba R
    Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study.
    Sultanik P; Lherault G; Bouzbib C; Ratziu V; Pais R; Mouri S; Thabut D; Rudler M
    Aliment Pharmacol Ther; 2024 Sep; 60(6):796-810. PubMed ID: 39034817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score.
    Kim A; Kang D; Choi SC; Cho J; Sinn DH; Gwak GY
    PLoS One; 2024; 19(3):e0301126. PubMed ID: 38530817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic characteristics of patients with MetALD: Caveats of a new definition.
    Petrie E; Gray M; Bril F
    Liver Int; 2024 Aug; ():. PubMed ID: 39152688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
    Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
    Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.